Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / FZD10

FZD10

Basics

Aliases:
This biomarker is also known as:
  • Fz10,
  • Fz-10,
  • FZ-10,
  • frizzled family receptor 10,
  • CD350,
  • frizzled homolog 10 (Drosophila),
  • frizzled-10,
  • frizzled 10, seven transmembrane spanning receptor,
  • FzE7,
  • frizzled homolog 10,
  • CD350 antigen,
  • Q9ULW2,
  • frizzled (Drosophila) homolog 10,
  • hFz10,

View in BioMuta

Description…

FZD10 is a member of the frizzled gene family. The frizzled gene family encodes 7-transmembrane domain proteins that are receptors for the Wingless type MMTV integration site family of signaling proteins (WNT signaling proteins). The highest levels of expression for FZD10 are seen in the placenta and fetal kidney, followed by fetal lung and brain. Using array analysis, expression of this intronless gene is significantly up-regulated in two cases of primary colon cancer.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: FZD10

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

FZD10 may be considered for further preclinical testing as a tumor biomarker.

Performance Comment

FZD10 was overexpressed in ovarian cancer relative to normal ovary and relative to a panel of normal organs. FZD10 was detected in vascular structures by in situ hybridization in five independent ovarian cancer samples. FZD10 was found in small and larger blood vessels. FZD10 showed limited or no expression by qRT-PCR in normal tissues.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.